JPRN-jRCTs051210132进行中（未招募）2 期
An exploratory, multicenter, open-label, randomized controlled trial of the efficacy and safety of trigger point injections for myofascial pain in patients with advanced cancer
Hasuo Hideaki0 个研究点目标入组 50 人开始时间: 2021年12月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Non-curable solid cancers
- •2) The reference diagnostic criteria of the MRS of Rivers are met
- •3) Average NRS of pain 24 hours before registration is greater than 4 or 4
- •4) Hospitalization at the registration within 14 days before registration
- •5) Age at registration is over 20 years old
- •6) Sustained main organ function
- •7) Witten informed consent
排除标准
- •1) There are cancer lesions in the same site as MPS by imaging examination within 4 weeks before registration
- •2) Change of regular analgesic drugs within 24 hours before registration
- •3) Psychiatric diseases or conditions that made communication difficult, such as cognitive impairment or disturbance of consciousness
- •4) Allergy to local anesthetics of the amide type
- •5) Pregnant and nursing
- •6) Patient who is considered ineligible for enrolling the study by a principal investigator or sub-investigator
研究者
相似试验
招募中
2 期
An exploratory, multicenter, randomized, open-label with blind evaluation, active controlled study to evaluate the safety and efficacy of Keramod (imiquimod 50 mg/g, Gel) compared with Aldara (imiquimod 50 mg/g, Cream) for the treatment of actinic keratosis in adults.Actinic keratosis2024-515667-60-00Laboratorios Ojer Pharma S.L.68
招募中
3 期
ong term treatment study of 0.02% STN1013900 ophthalmic solution alone or in combination with either 0.005% Latanoprost ophthalmic solution, or 0.5%Timolol ophthalmic solution in subjects with open angle glaucoma or ocular hypertensioJPRN-jRCT2031210125Sakamoto Kayoko150
尚未招募
4 期
Paximusâ?¢ Randomized Controlled TrialCTRI/2019/05/018886Meril Life Sciences Pvt Ltd
进行中（未招募）
不适用
A phase I/II trial for evaluating both safety and preliminary efficacy of one cycle of Promethera HepaStem® in Urea Cycle Disorders and Crigler-Najjar Syndrome patientsCrigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are six disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia, argininosuccinic aciduria and argininemiaMedDRA version: 17.0Level: LLTClassification code 10021601Term: Inborn error of metabolism NOSSystem Organ Class: 100000004850EUCTR2011-004074-28-GBPromethera Biosciences21
尚未招募
2 期
comparative clinical trial to evaluate safety and efficacy of test drug plus standard of care and standard of care alone in COVID 19 Acute Respiratory Distress Syndrome (ARDS) patients with non-invasive ventilation.CTRI/2021/12/038778Reliance Life Sciences Pvt Ltd